Finance

Lists
Why is AKTS down 10.81%?
Dive Deeper
AKTS:NASDAQ
Aktis Oncology Inc
$ 19.72
-10.81%
(-2.39) 1D
$ 20.09
+1.88% (+0.37)
After hours
Closed: 9-р сарын 23, 16:00:01 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
$ 21.87
High
$ 21.87
Low
$ 19.67
Mkt. cap
1.06 тэрбум
Avg. vol.
402.70 мян
Volume
3.00
52-wk high
$ 34.19
52-wk low
$ 14.72
EPS
-$ 1.42
Shares outstanding
53.75 сая
No. of employees
79
Open
$ 21.87
High
$ 21.87
Low
$ 19.67
Mkt. cap
1.06 тэрбум
Avg. vol.
402.70 мян
Volume
3.00
52-wk high
$ 34.19
52-wk low
$ 14.72
EPS
-$ 1.42
Shares outstanding
53.75 сая
No. of employees
79
News stories
From web sources and news partners
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
HeadquartersБостон, Массачусеттс, Америкийн Нэгдсэн Улс
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current $ 19.72
$ 40.00 (+102.84%)
Average
$ 35.80 (+81.54%)
Lowest
$ 33.00 (+67.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeff Jones
Oppenheimer
Buy
Initiated
$ 40.00
+102.8%
09/09/2026
David Nierengarten
Wedbush
Buy
Initiated
$ 35.00
+77.5%
08/19/2026
David Lebowitz
BMO Capital
Buy
Initiated
$ 37.00
+87.6%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$ 37.00
+87.6%
08/18/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$ 34.00
+72.4%
08/14/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$ 33.00
+67.3%
08/14/2026
Alexandra Ramsey
William Blair
Buy
Maintained
-
-
08/14/2026
Christopher Raymond
Raymond James
Buy
Initiated
$ 40.00
+102.8%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$ 35.00
+77.5%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
$ 18.75
-4.9%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
$ 18.60
-5.7%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
$ 32.00
+62.3%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
$ 31.00
+57.2%
02/03/2026
Last report
2026 оны 8-р сарын 13
Fiscal period
Q2 2026
EPS / Est. (USD)
-$ 0.44 / -$ 0.43
-1.17%miss
Revenue / Est. (USD)
3.38 сая / 2.58 сая
+30.99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 оны 6-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
1.60 сая
1.87 сая
3.23 сая
3.38 сая
Cost of goods sold
18.63 сая
16.49 сая
20.04 сая
25.28 сая
Cost of revenue
18.63 сая
16.49 сая
20.04 сая
25.28 сая
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.94 сая
2.75 сая
5.90 сая
7.00 сая
Operating expense
3.94 сая
2.75 сая
5.90 сая
7.00 сая
Total operating expenses
22.56 сая
19.24 сая
25.93 сая
32.28 сая
Operating income
-20.96 сая
-17.38 сая
-22.71 сая
-28.90 сая
Other non operating income
-20.00 мян
-11.00 мян
-3.00 мян
-10.00 мян
EBT including unusual items
-18.08 сая
-15.14 сая
-18.32 сая
-24.14 сая
EBT excluding unusual items
-18.08 сая
-15.14 сая
-18.32 сая
-24.14 сая
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18.08 сая
-15.14 сая
-18.32 сая
-24.14 сая
Net profit margin
-1,128.98%
-809.52%
-567.86%
-713.48%
Earnings per share
-
-
-0.38
-0.44
Interest and investment income
2.91 сая
2.25 сая
4.38 сая
4.76 сая
Interest expense
-
-
-
-
Net interest expenses
2.91 сая
2.25 сая
4.38 сая
4.76 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.41 сая
-16.68 сая
-22.05 сая
-28.02 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс